medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2011, Number 2

<< Back Next >>

Rev Invest Clin 2011; 63 (2)

A pharmacoepidemiological study of potential drug interactions and their determinant factors in hospitalized patients

Mino-León D, Galván-Plata ME, Doubova SV, Flores-Hernandez S, Reyes-Morales H

Language: Spanish
References: 29
Page: 170-178
PDF size: 81.00 Kb.


ABSTRACT

Background. Prescription with more than one drug increases the risk of drug-drug interaction (D-DI), therapeutic failure, high pharmacological effect, or adverse events. The objectives of this study were to estimate the frequency of potential drug-drug interactions in prescriptions for hospitalized patients, and to identify the associated factors for these prescriptions. Material and methods. A secondary data analysis of a cohort was carried out, including 284 patients at the internal medicine ward in a third level hospital in Mexico City. Age, gender, diagnosis at admission, days of hospitalization, prescription and administration of the drugs were analyzed. The potential D-DI were identified and registered according to the severity. Descriptive and crude association analyses including the outcome variable and co variables, and Poisson regression analysis for adjusting the variables were performed. Results. The median of age was 53 ± 18 years old; 53% of the patients were women, and 34% were older than 65 years of age. Sixty-three percent of the patients received one prescription identified as potential D-DI, and 33.5% of these prescriptions were “major D-DIs”. The most frequently pairs of drugs prescribed were: fluoroquinolones-hypoglycemics (20.5%), enoxaparin- nonsteroidal antiinflammatory drugs or anticoagulants (18.1%), furosemide- angiotensin converting enzyme inhibitors (ACE inhibitor) (12.2%), alopurinol- ACE inhibitor (9%), and spironolactone- ACE inhibitor (9%). Thirty-three percent of patients older than 65 years of age received a prescription including one potential D-DI. Gender and the number of drugs received were associated factors to the potential D-DI. Conclusions: High percentage of prescriptions with potential D-DI makes necessary to implement educational programs or alert strategies including the identified associated factors, aimed to improve the quality of prescriptions and to reduce the risks for hospitalized patients.


REFERENCES

  1. Quin DI, Day RO (1997): “Clinically important drug interactions” en Speight TM, Holford NHG (eds.) Avery´s Drug Treatment. Cap 7, Adis International; Barcelona, Spain: p. 301-338.

  2. Crucial-Souza JM, Thomson JC. A pharmacoepidemiologic study of drug interactions in Brazilian teaching hospital. Clinics 2006; 61: 515-20.

  3. Wiffen P, Gill M, Edwards J, Moore A. Adverse drug reactions in hospital patients. A systematic review of the prospective and retrospective studies. Bandolier Extra [Revista electronica] junio 2002 [consultado 05/01/10]: Disponible en: http:// www.jr2.ox.ac.uk/bandolier/Extraforbando/ADRM.pdf

  4. Becker ML, Caspers PWJ, Kallewaard M, Bruinink RJ, Kylstra NB, Heisterkamp S et al. Determinants of potential drug-drug interaction associated dispensing in community pharmacies in the Netherlands. Pharm World Sci 2007; 29: 51-7.

  5. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley T, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 2004; 329: 15-9.

  6. Ibáñez A, Alcalá M, García J, Puche E. Interacciones medicamentosas en pacientes de un servicio de medicina interna. Farm Hosp 2008; 32: 293-97.

  7. Crucial-Souza JM, Thomson JC. Prevalence of potential drugdrug interactions and its associated factors in Brazilian teaching hospital. J Pharm Pharmaceut Sci 2006; 9: 427-33.

  8. Doubova SV, Reyes H, Torres L, Suárez M. Potential drugdrug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. BMC Health Services Research 2007, 7:147-54.

  9. Mino-León D, Reyes-Morales H, Galván Plata ME, Ponce- Monter H, Palma-Aguirre JA, Amato D, et al . Drug treatment of hipertensión: compliance and adverse reactions in a cohort of hypertensive patients in primary care setting. Rev Invest Clin 2007; 59: 8-14.

  10. Costa AJ. Potential drug interactions in an ambulatory geriatric population. Fam Prac 1991; 8: 234-36.

  11. Doubova SV, Torres-Arreola LP, Rosas-Carrasco O, Pérez- Cuevas R. Calidad de la prescripción en los adultos mayores con síndrome doloroso de origen no oncológico usuarios de los servicios de medicina familiar. Rev Invest Clin 2007; 59: 428-36.

  12. Mahmood M, Malone DC, Skrepnek GH, Abarca J, Armstrong EP, Murphy JE, et al . Potential drug–drug interactions within Veterans Affairs medical centers. Am J Health-Syst Pharm 2007; 64: 1500-05.

  13. Passarelli MC, Jabcob-Filho W, Figueras A. Adverse drug reactions in an elderly hospitalized population. Inappropriate prescription is a leading cause. Drugs Aging 2005; 22: 767-77.

  14. Viramontes-Madrid JL, Jerjes-Sánchez C, Pelaez-Ballestas I, Aguilar-Chiu A, Hernández-Garduño A. Riesgo de Interacciones medicamentosas. Combinaciones de medicamentos asociados a arritmia ventricular. Rev Invest Clin 2002; 54: 192-97.

  15. Klasco RK (editor): DRUG-REAX® System. Thomson MICROMEDEX, Greenwood Vllage, Colorado (Edition expires 2008).

  16. Parfitt K. Martinadale. The complete drug reference. 32 ed. London: Pharmaceutical Press, 1999.

  17. WHO – World Health Organization. Anatomic Therapeutic and Chemical Classification of Drugs. [Consultado 11/01/2009 en: http://www.whocc.no/atcdd.

  18. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 2003; 20: 21-33.

  19. StataCorp. Stata Statistical Software: Release 10.0. College Station, TX: Stata Corporation, 2007.

  20. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163: 2716-24.

  21. Köhler GI, Bode-Böger SM, Busse R, Hoopmann M, Welte T, Böger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000; 38: 504-13.

  22. Braga TB, Pfaffenbach G, Peterson D, Berteli de Azevedo M, Bergsten-Mendes G. Point prevalence of drug prescriptions for elderly and non-elderly inpatients in a teaching hospital. Sao Paulo Med J 2004; 122: 48-52.

  23. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al . Systematic Overview of Warfarin and Its Drug and Food Interactions. Arch Intern Med 2005; 165: 1095-1106.

  24. Glassman PA, Simon B, Belperio P, Lanto A. Improving recognition of drug interactions benefits and barriers to using automated drug alerts. Medical Care 2002; 40: 1161-71.

  25. Martín MT, Codina C, Tuset M, Carné X, Nogué S, Ribas J. Problemas relacionados con la medicación como causa del ingreso hospitalario. Med Clin (Barc) 2002; 118: 205-10.

  26. Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998; 12: 485-94.

  27. Moura C, Acurcio F, Belo N. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharmaceut Sci 2009; 12: 266-72.

  28. Gagne JJ, Maio V, Rabinowitz C. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. J Clin Pharm Ther 2008; 33: 141- 51.

  29. Bjorkman IK, Fastbom J, Schmidt IK, Bernsten CB. Drugdrug interactions in the elderly. Ann Pharmacother 2002; 36: 1675-81.




2020     |     www.medigraphic.com